Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis |
Zhao, Jing-Yi
(Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University)
Ma, Xue-Lei (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) Li, Yan-Yan (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) Zhang, Bing-Lan (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) Li, Min-Min (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) Ma, Xue-Lei (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) Liu, Lei (Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University) |
1 | Uzel EK, Ekmekcioglu O, Elicin O, Halac M & Uzel OE (2013). Is FDG -PET-CT a valuable tool in prediction of persistent disease in head and neck cancer. Asian Pac J Cancer Prev, 14, 4847-51. 과학기술학회마을 DOI ScienceOn |
2 | Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM & Kleijnen J (2003). The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol, 3, 25. DOI ScienceOn |
3 | Wilson CB, Young HE, Ott RJ et al (1995). Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med, 22, 508-13. DOI |
4 | Sanchez D, Zudaire JJ, Fernandez JM et al (2002). 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int, 89, 912-6. DOI ScienceOn |
5 | Nichols CR (1998). Testicular cancer. Curr Probl Cancer, 22, 187-274. DOI ScienceOn |
6 | Oechsle K, Hartmann M, Brenner W et al (2008) [18F] Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol, 26, 5930-5. DOI ScienceOn |
7 | Rohren EM, Turkington TG & Coleman RE (2004). Clinical applications of PET in oncology. Radiology, 231, 305-32. DOI ScienceOn |
8 | Siekiera J, Malkowski B, Jozwicki W et al (2012). Can we rely on PET in the follow-up of advanced seminoma patients? Urol Int, 88, 405-9. DOI ScienceOn |
9 | Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA & Oyen WJ (2002). The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int, 89, 549-56. DOI ScienceOn |
10 | Stephens AW, Gonin R, Hutchins GD & Einhorn LH (1996). Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol, 14, 1637-41. |
11 | Tsatalpas P, Beuthien-Baumann B, Kropp J et al (2002). Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int, 68, 157-63. DOI ScienceOn |
12 | Karapetis CS, Strickland AH, Yip D, Steer C & Harper P G (2003). Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Intern Med J, 33, 427-35. DOI ScienceOn |
13 | Kollmannsberger C, Oechsle K, Dohmen B M et al (2002). Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer, 94, 2353-62. DOI ScienceOn |
14 | Huddart R A (2003). Use of FDG-PET in testicular tumours. Clin Oncol (R Coll Radiol), 15, 123-7. DOI ScienceOn |
15 | Johns Putra L, Lawrentschuk N, Ballok Z et al (2004). 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology, 64, 1202-7. DOI ScienceOn |
16 | Lassen U, Daugaard G, Eigtved A et al (2003). Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging, 30, 396-402. DOI |
17 | Lewis DA, Tann M, Kesler K et al (2006). Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. J Clin Oncol, 24, e54-5. DOI |
18 | McGee S (2002). Simplifying likelihood ratios. J Gen Intern Med, 17, 646-9. |
19 | Moses LE, Shapiro D & Littenberg B (1993). Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med, 12, 1293-316. DOI ScienceOn |
20 | Mutlu H, Buyukcelik A, Erden A et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6. 과학기술학회마을 DOI ScienceOn |
21 | Deeks JJ, Macaskill P & Irwig L (2005). The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 58, 882-93. DOI ScienceOn |
22 | Devesa SS, Blot WJ, Stone BJ et al (1995). Recent cancer trends in the United States. J Natl Cancer Inst, 87, 175-82. DOI ScienceOn |
23 | Ganjoo KN, Chan RJ, Sharma M & Einhorn LH (1999). Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol, 17, 3457-60. |
24 | Hain S F (2005). Positron emission tomography in uro-oncology. Cancer Imaging, 5, 1-7. DOI ScienceOn |
25 | Hain SF, O’Doherty MJ, Timothy AR et al (2000). Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer, 83, 863-9. DOI ScienceOn |
26 | Halfpenny W, Hain SF, Biassoni L et al (2002). FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer, 86, 512-6. DOI ScienceOn |
27 | Hanley JA & McNeil BJ (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143, 29-36. DOI |
28 | Hinz S, Schrader M, Kempkensteffen C et al (2008). The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol, 179, 936-40; discussion 940. DOI ScienceOn |
29 | Hofer C, Kubler H, Hartung R, Breul J & Avril N (2001). Diagnosis and monitoring of urological tumors using positron emission tomography. Eur Urol, 40, 481-7. |
30 | Hoekstra OS, Ossenkoppele GJ, Golding R et al (1993). Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med, 34, 1706-10. |
31 | Chen YK, Yeh CL, Tsui CC et al (2011). F-18 FDG PET for evaluation of bone marrow involvement in non-Hodgkin lymphoma: a meta-analysis. Clin Nucl Med, 36, 553-9. DOI ScienceOn |
32 | Becherer A (2011). PET in testicular cancer. Methods Mol Biol, 727, 225-41. DOI ScienceOn |
33 | Becherer A, De Santis M, Karanikas G et al (2005). FDG PET is superior to CT in the prediction of viable tumour in postchemotherapy seminoma residuals. Eur J Radiol, 54, 284-8. DOI ScienceOn |
34 | Bokemeyer C, Kollmannsberger C, Oechsle K et al (2002) Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [ (18)F]FDG PET. Br J Cancer, 86, 506-11. DOI ScienceOn |
35 | Cremerius U, Wildberger JE, Borchers H et al (1999). Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Urology, 54, 900-4. DOI ScienceOn |
36 | Cremerius U, Effert PJ, Adam G et al (1998). FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med, 39, 815-22. |
37 | Czernin J (2002). Clinical applications of FDG-PET in oncology. Acta Med Austriaca, 29, 162-70. DOI ScienceOn |
38 | Dalal PU, Sohaib SA & Huddart R (2006). Imaging of testicular germ cell tumours. Cancer Imaging, 6, 124-34. DOI |
39 | de Wit M, Brenner W, Hartmann M et al (2008). [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours:results of the German multicentre trial. Ann Oncol, 19, 1619-23. DOI ScienceOn |
40 | De Santis M, Becherer A, Bokemeyer C et al (2004). 2-18fluorodeoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma:an update of the prospective multicentric SEMPET trial. J Clin Oncol, 22, 1034-9. DOI ScienceOn |
41 | Akbulut Z, Canda AE, Atmaca AF et al (2011). Is positron emission tomography reliable to predict post-chemotherapy retroperitoneal lymph node involvement in advanced germ cell tumors of the testis? Urol J, 8, 120-6. |
42 | Albers P, Bender H, Yilmaz H et al (1999). Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology, 53, 808-11. DOI ScienceOn |
43 | Albers P, Weissbach L, Krege S et al (2004). Prediction of necrosis after chemotherapy of advanced germ cell tumors:results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol, 171, 1835-8. DOI ScienceOn |
44 | Antoch G, Saoudi N, Kuehl H et al (2004). Accuracy of wholebody dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors:comparison with CT and PET. J Clin Oncol, 22, 4357-68. DOI ScienceOn |
45 | Bachner M, Loriot Y, Gross-Goupil M et al (2012). 2-(1)(8)fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol, 23, 59-64. DOI ScienceOn |
46 | Saunders CA, Dussek JE, O’Doherty MJ & Maisey MN (1999). Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg, 67, 790-7. DOI ScienceOn |
47 | Yetisyigit T, Babacan N, Urun Y et al (2014). Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors. Asian Pac J Cancer Prev, 15, 831-5. 과학기술학회마을 DOI ScienceOn |
![]() |